Gliomas: Predicting Time to Progression or Survival with Cerebral Blood Volume Measurements at Dynamic Susceptibility-weighted Contrast-enhanced Perfusion MR Imaging

Purpose: To retrospectively determine whether relative cerebral blood volume (CBV) measurements can be used to predict clinical outcome in patients with high-grade gliomas (HGGs) and low-grade gliomas (LGGs) and specifically whether patients who have gliomas with a high initial relative CBV have more rapid progression than those who have gliomas with a low relative CBV.

Materials and Methods: Approval for this retrospective HIPAA-compliant study was obtained from the Institutional Board of Research Associates, with waiver of informed consent. One hundred eighty-nine patients (122 male and 67 female patients; median age, 43 years; range, 4–80 years) were examined with dynamic susceptibility-weighted contrast material–enhanced perfusion magnetic resonance (MR) imaging and were followed up clinically with MR imaging (median follow-up, 334 days). Log-rank tests were used to evaluate the association between relative CBV and time to progression by using Kaplan-Meier curves. Binary logistic regression was used to determine whether age, sex, and relative CBV were associated with an adverse event (progressive disease or death).

Results: Values for the mean relative CBV for patients according to each clinical response were as follows: 1.41 ± 0.13 (standard deviation) for complete response (n = 4), 2.36 ± 1.78 for stable disease (n = 41), 4.84 ± 3.32 for progressive disease (n = 130), and 3.82 ± 1.93 for death (n = 14). Kaplan-Meier estimates of median time to progression in days indicated that patients with a relative CBV of less than 1.75 had a median time to progression of 3585 days, whereas patients with a relative CBV of more than 1.75 had a time to progression of 265 days. Age and relative CBV were also independent predictors for clinical outcome.

Conclusion: Dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging can be used to predict median time to progression in patients with gliomas, independent of pathologic findings. Patients who have HGGs and LGGs with a high relative CBV (>1.75) have a significantly more rapid time to progression than do patients who have gliomas with a low relative CBV.

© RSNA, 2008

References

  • 1 Burger PC, Vogel FS, Green SB, Strike TA. Glioblastoma multiforme and anaplastic astrocytoma: pathologic criteria and prognostic implications. Cancer 1985; 56: 1106–1111. Crossref, MedlineGoogle Scholar
  • 2 Ringertz N. Grading of gliomas. Acta Pathol Microbiol Scand 1950; 27: 51–64. MedlineGoogle Scholar
  • 3 Kleihues P, Cavanee P. WHO classification of tumors: pathology and genetic of tumours of the nervous system. Lyon, France: International Agency for Research on Cancer, 2000. Google Scholar
  • 4 Kleihues P, Soylemezoglu F, Schauble B, Scheithauer BW, Burger PC. Histopathology, classification, and grading of gliomas. Glia 1995; 15: 211–221. Crossref, MedlineGoogle Scholar
  • 5 Daumas-Duport C, Scheithauer B, O'Fallon J, Kelly P. Grading of astrocytomas: a simple and reproducible method. Cancer 1988; 62: 2152–2165. Crossref, MedlineGoogle Scholar
  • 6 Jackson RJ, Fuller GN, Abi-Said D, et al. Limitations of stereotactic biopsy in the initial management of gliomas. Neuro Oncol 2001; 3: 193–200. Crossref, MedlineGoogle Scholar
  • 7 Prayson RA, Agamanolis DP, Cohen ML, et al. Interobserver reproducibility among neuropathologists and surgical pathologists in fibrillary astrocytoma grading. J Neurol Sci 2000; 175: 33–39. Crossref, MedlineGoogle Scholar
  • 8 Coons SW, Johnson PC, Scheithauer BW, Yates AJ, Pearl DK. Improving diagnostic accuracy and interobserver concordance in the classification and grading of primary gliomas. Cancer 1997; 79: 1381–1393. Crossref, MedlineGoogle Scholar
  • 9 Gilles FH, Brown WD, Leviton A, et al. Limitations of the World Health Organization classification of childhood supratentorial astrocytic tumors. Children Brain Tumor Consortium. Cancer 2000; 88: 1477–1483. Google Scholar
  • 10 Cairncross JG, Ueki K, Zlatescu MC, et al. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst 1998; 90: 1473–1479. Crossref, MedlineGoogle Scholar
  • 11 Cha S. Update on brain tumor imaging: from anatomy to physiology. AJNR Am J Neuroradiol 2006; 27: 475–487. MedlineGoogle Scholar
  • 12 Cha S. Perfusion MR imaging: basic principles and clinical applications. Magn Reson Imaging Clin N Am 2003; 11: 403–413. Crossref, MedlineGoogle Scholar
  • 13 Law M, Yang S, Wang H, et al. Glioma grading: sensitivity, specificity, and predictive values of perfusion MR imaging and proton MR spectroscopic imaging compared with conventional MR imaging. AJNR Am J Neuroradiol 2003; 24: 1989–1998. MedlineGoogle Scholar
  • 14 Law M, Yang S, Babb JS, et al. Comparison of cerebral blood volume and vascular permeability from dynamic susceptibility contrast-enhanced perfusion MR imaging with glioma grade. AJNR Am J Neuroradiol 2004; 25: 746–755. MedlineGoogle Scholar
  • 15 Lev MH, Ozsunar Y, Henson JW, et al. Glial tumor grading and outcome prediction using dynamic spin-echo MR susceptibility mapping compared with conventional contrast-enhanced MR: confounding effect of elevated rCBV of oligodendrogliomas. AJNR Am J Neuroradiol 2004; 25: 214–221. [Published correction appears in AJNR Am J Neuroradiol 2004;25(3):B1.] MedlineGoogle Scholar
  • 16 Lev MH, Rosen BR. Clinical applications of intracranial perfusion MR imaging. Neuroimaging Clin N Am 1999; 9: 309–331. MedlineGoogle Scholar
  • 17 Shin JH, Lee HK, Kwun BD, et al. Using relative cerebral blood flow and volume to evaluate the histopathologic grade of cerebral gliomas: preliminary results. AJR Am J Roentgenol 2002; 179: 783–789. Crossref, MedlineGoogle Scholar
  • 18 Sugahara T, Korogi Y, Shigematsu Y, et al. Value of dynamic susceptibility contrast magnetic resonance imaging in the evaluation of intracranial tumors. Top Magn Reson Imaging 1999; 10: 114–124. Crossref, MedlineGoogle Scholar
  • 19 Aronen HJ, Perkio J. Dynamic susceptibility contrast MRI of gliomas. Neuroimaging Clin N Am 2002; 12: 501–523. Crossref, MedlineGoogle Scholar
  • 20 Burger PC, Vogel FS. The brain: tumors. In: Burger PC, Vogel FS, eds. Surgical pathology of the central nervous system and its coverings. New York, NY: Wiley, 1982; 223–266. Google Scholar
  • 21 Law M, Oh S, Babb JS, et al. Low-grade gliomas: dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging—prediction of patient clinical response. Radiology 2006; 238: 658–667. LinkGoogle Scholar
  • 22 Law M, Oh S, Johnson G, et al. Perfusion magnetic resonance imaging predicts patient outcome as an adjunct to histopathology: a second reference standard in the surgical and nonsurgical treatment of low-grade gliomas. Neurosurgery 2006; 58: 1099–1107. Crossref, MedlineGoogle Scholar
  • 23 Ball WS Jr, Holland SK. Perfusion imaging in the pediatric patient. Magn Reson Imaging Clin N Am 2001; 9: 207–230, ix. Crossref, MedlineGoogle Scholar
  • 24 Jaffe CC. Measures of response: RECIST, WHO, and new alternatives. J Clin Oncol 2006; 24: 3245–3251. Crossref, MedlineGoogle Scholar
  • 25 Levin VA, Hess KR, Choucair A, et al. Phase III randomized study of postradiotherapy chemotherapy with combination alpha-difluoromethylornithine-PCV versus PCV for anaplastic gliomas. Clin Cancer Res 2003; 9: 981–990. MedlineGoogle Scholar
  • 26 Rosen BR, Belliveau JW, Buchbinder BR, et al. Contrast agents and cerebral hemodynamics. Magn Reson Med 1991; 19: 285–292. Crossref, MedlineGoogle Scholar
  • 27 Rosen BR, Belliveau JW, Vevea JM, Brady TJ. Perfusion imaging with NMR contrast agents. Magn Reson Med 1990; 14: 249–265. Crossref, MedlineGoogle Scholar
  • 28 Wetzel SG, Cha S, Johnson G, et al. Relative cerebral blood volume measurements in intracranial mass lesions: interobserver and intraobserver reproducibility study. Radiology 2002; 224: 797–803. LinkGoogle Scholar
  • 29 Shaw EG, Tatter SB, Lesser GJ, Ellis TL, Stanton CA, Stieber VW. Current controversies in the radiotherapeutic management of adult low-grade glioma. Semin Oncol 2004; 31: 653–658. Crossref, MedlineGoogle Scholar
  • 30 Shaw EG, Wisoff JH. Prospective clinical trials of intracranial low-grade glioma in adults and children. Neuro Oncol 2003; 5: 153–160. Crossref, MedlineGoogle Scholar
  • 31 Schmainda KM, Rand SD, Joseph AM, et al. Characterization of a first-pass gradient-echo spin-echo method to predict brain tumor grade and angiogenesis. AJNR Am J Neuroradiol 2004; 25: 1524–1532. MedlineGoogle Scholar
  • 32 Cao Y, Tsien CI, Nagesh V, et al. Survival prediction in high-grade gliomas by MRI perfusion before and during early stage of RT. Int J Radiat Oncol Biol Phys 2006; 64: 876–885. [Published correction appears in Int J Radiat Oncol Biol Phys 2006;65(3):960.] Crossref, MedlineGoogle Scholar

Article History

Published in print: 2008